Literature DB >> 12224952

A solid-phase approach to mouse melanocortin receptor agonists derived from a novel thioether cyclized peptidomimetic scaffold.

Jon Bondebjerg1, Zhimin Xiang, Rayna M Bauzo, Carrie Haskell-Luevano, Morten Meldal.   

Abstract

The solid-phase synthesis of a novel thioether cyclized peptidomimetic scaffold, displaying functionality at the i to i + 3 positions, is reported. The thioether bridge is formed on-bead by an intramolecular reaction between a chloroacetylated reduced peptide bond and the free thiol from a cysteine. The crude products were obtained in moderate to very high purity. A series of 19 compounds were prepared and tested for agonist activity at the mouse melanocortin receptors 1, 3, 4, and 5 (mMC1-5R). From these results, several compounds were identified as having low micromolar agonist activity at the mMC1R and mMC4R. The former is involved in skin pigmentation and animal coat coloration. The latter is involved in the regulation of appetite and food intake and is currently a drug target for potential treatment of obesity. The most potent compound 1n with the pharmacophore motif "His-DPhe-Arg-Trp" was identified as having an EC(50) value of 165 nM at mMC1R, 7600 nM at mMC3R, 650 nM at mMC4R, and 335 nM at mMC5R. In addition, some of the compounds showed moderate selectivity for the mMC1R.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12224952     DOI: 10.1021/ja0123913

Source DB:  PubMed          Journal:  J Am Chem Soc        ISSN: 0002-7863            Impact factor:   15.419


  12 in total

Review 1.  The Melanocortin Receptor System: A Target for Multiple Degenerative Diseases.

Authors:  Minying Cai; Victor J Hruby
Journal:  Curr Protein Pept Sci       Date:  2016       Impact factor: 3.272

2.  Structure-activity relationships of peptides incorporating a bioactive reverse-turn heterocycle at the melanocortin receptors: identification of a 5800-fold mouse melanocortin-3 receptor (mMC3R) selective antagonist/partial agonist versus the mouse melanocortin-4 receptor (mMC4R).

Authors:  Anamika Singh; Marvin Dirain; Rachel Witek; James R Rocca; Arthur S Edison; Carrie Haskell-Luevano
Journal:  J Med Chem       Date:  2013-03-25       Impact factor: 7.446

Review 3.  Bench-top to clinical therapies: A review of melanocortin ligands from 1954 to 2016.

Authors:  Mark D Ericson; Cody J Lensing; Katlyn A Fleming; Katherine N Schlasner; Skye R Doering; Carrie Haskell-Luevano
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2017-03-29       Impact factor: 5.187

4.  Pharmacological characterization of 30 human melanocortin-4 receptor polymorphisms with the endogenous proopiomelanocortin-derived agonists, synthetic agonists, and the endogenous agouti-related protein antagonist.

Authors:  Zhimin Xiang; Bettina Proneth; Marvin L Dirain; Sally A Litherland; Carrie Haskell-Luevano
Journal:  Biochemistry       Date:  2010-06-08       Impact factor: 3.162

5.  Incorporation of a bioactive reverse-turn heterocycle into a peptide template using solid-phase synthesis to probe melanocortin receptor selectivity and ligand conformations by 2D 1H NMR.

Authors:  Anamika Singh; Andrzej Wilczynski; Jerry R Holder; Rachel M Witek; Marvin L Dirain; Zhimin Xiang; Arthur S Edison; Carrie Haskell-Luevano
Journal:  J Med Chem       Date:  2011-02-09       Impact factor: 7.446

6.  One-pot high-throughput synthesis of beta-turn cyclic peptidomimetics via "volatilizable" supports.

Authors:  Yangmei Li; Yongping Yu; Marc Giulianotti; Richard A Houghten
Journal:  J Org Chem       Date:  2009-03-06       Impact factor: 4.354

7.  Beta-turn secondary structure and melanocortin ligands.

Authors:  Erica M Haslach; Jay W Schaub; Carrie Haskell-Luevano
Journal:  Bioorg Med Chem       Date:  2008-03-04       Impact factor: 3.641

8.  Synthesis and Structure-Activity Relationships of Substituted Urea Derivatives on Mouse Melanocortin Receptors.

Authors:  Anamika Singh; Johannes Kast; Marvin L S Dirain; Huisuo Huang; Carrie Haskell-Luevano
Journal:  ACS Chem Neurosci       Date:  2015-12-24       Impact factor: 4.418

9.  Discovery of Nanomolar Melanocortin-3 Receptor (MC3R)-Selective Small Molecule Pyrrolidine Bis-Cyclic Guanidine Agonist Compounds Via a High-Throughput "Unbiased" Screening Campaign.

Authors:  Skye R Doering; Katie Freeman; Ginamarie Debevec; Phaedra Geer; Radleigh G Santos; Travis M Lavoi; Marc A Giulianotti; Clemencia Pinilla; Jon R Appel; Richard A Houghten; Mark D Ericson; Carrie Haskell-Luevano
Journal:  J Med Chem       Date:  2021-04-22       Impact factor: 7.446

Review 10.  Heterocycles as a Peptidomimetic Scaffold: Solid-Phase Synthesis Strategies.

Authors:  Aizhan Abdildinova; Mark J Kurth; Young-Dae Gong
Journal:  Pharmaceuticals (Basel)       Date:  2021-05-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.